# Clinical Trial Landscape: 09_prostate_brca2

*Generated: 2026-01-05 18:32:01*

## Summary

- **Total Trials**: 100
- **Flagged for Review**: 0
- **Search Terms Used**: 10

## Phase Distribution

| Phase | Count | Distribution |
|-------|-------|--------------|
| Phase 2 | 28 | █████ 28.0% |
| Unknown | 21 | ████ 21.0% |
| Phase 1 | 16 | ███ 16.0% |
| Phase 1/Phase 2 | 14 | ██ 14.0% |
| Phase 3 | 10 | ██ 10.0% |
| Not Applicable | 9 | █ 9.0% |
| Phase 2/Phase 3 | 2 |  2.0% |

## Status Distribution

- **Recruiting**: 94 (94.0%)
- **Enrolling by invitation**: 3 (3.0%)
- **Not yet recruiting**: 3 (3.0%)

## Top Sponsors

| Sponsor | Trial Count |
|---------|-------------|
| National Cancer Institute (NCI) | 6 |
| SWOG Cancer Research Network | 4 |
| Mayo Clinic | 4 |
| Novartis Pharmaceuticals | 4 |
| Pfizer | 3 |
| Jonsson Comprehensive Cancer Center | 3 |
| University of Utah | 3 |
| Massachusetts General Hospital | 2 |
| VA Office of Research and Development | 2 |
| Zenith Epigenetics | 2 |
| Amgen | 2 |
| Fred Hutchinson Cancer Center | 2 |
| Weill Medical College of Cornell University | 2 |
| University of California, San Diego | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |

## Interventions

| Intervention | Occurrences |
|--------------|-------------|
| Biospecimen Collection | 13 |
| Enzalutamide | 11 |
| Computed Tomography | 10 |
| Magnetic Resonance Imaging | 8 |
| Positron Emission Tomography | 7 |
| Abiraterone | 5 |
| Docetaxel | 5 |
| Olaparib | 5 |
| Questionnaire Administration | 5 |
| Prednisone | 4 |
| Bone Scan | 4 |
| AAA817 | 4 |
| Carboplatin | 3 |
| Darolutamide | 3 |
| Gallium Ga 68 Gozetotide | 3 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 3 |
| Single Photon Emission Computed Tomography | 3 |
| Cabazitaxel | 3 |
| MRI | 2 |
| Leuprolide Acetate | 2 |

## Geographic Distribution

| Country | Trial Count |
|---------|-------------|
| United States | 100 |
| Australia | 14 |
| Spain | 12 |
| China | 11 |
| United Kingdom | 11 |
| Canada | 10 |
| Japan | 10 |
| South Korea | 10 |
| Taiwan | 10 |
| France | 9 |
| Brazil | 7 |
| Germany | 7 |
| Italy | 7 |
| Turkey (Türkiye) | 6 |
| Poland | 6 |

## Search Term Provenance

| Term | Source | Confidence |
|------|--------|------------|
| BRCA2 germline mutation | manual | 1.0 |
| prostate cancer | manual | 1.0 |
| BRCA2 germline mutation prostate cancer | manual | 1.0 |
| BRCA2 germline mutation mCRPC | llm | 0.9 |
| BRCA2 mutation metastatic castration-resistant prostate cancer | llm | 0.9 |
| mCRPC | llm | 0.8 |
| metastatic castration-resistant prostate cancer | llm | 0.8 |
| BRCA2 mutation | llm | 0.9 |
| BRCA2mutation | llm | 0.8 |
| BRCA2-mutation | llm | 0.8 |

## All Trials

| NCT ID | Phase | Status | Sponsor | Title |
|--------|-------|--------|---------|-------|
| [NCT06960798](https://clinicaltrials.gov/study/NCT06960798) | N/A | Not yet recruiting | University of Oklaho... | Characterizing the Genomic Landscap... |
| [NCT06615752](https://clinicaltrials.gov/study/NCT06615752) | Phase 1/Phase 2 | Recruiting | Charles Drew Univers... | A Phase I/II Study to Determine the... |
| [NCT06538636](https://clinicaltrials.gov/study/NCT06538636) | Not Applicable | Not yet recruiting | VA Office of Researc... | Prediction Augmented Screening Init... |
| [NCT06906471](https://clinicaltrials.gov/study/NCT06906471) | Phase 1/Phase 2 | Not yet recruiting | Antelope Surgical So... | A Single-Arm, Blinded, Fluorescent ... |
| [NCT06894511](https://clinicaltrials.gov/study/NCT06894511) | Phase 2 | Recruiting | Novartis Pharmaceuti... | A Phase II, Open-label, Multi-Cente... |
| [NCT06883838](https://clinicaltrials.gov/study/NCT06883838) | Not Applicable | Enrolling by invitation | The University of Te... | Enhancing Primary Care Capacity for... |
| [NCT06855277](https://clinicaltrials.gov/study/NCT06855277) | Phase 3 | Recruiting | Novartis Pharmaceuti... | A Phase III, Open-label, Multi-cent... |
| [NCT06995898](https://clinicaltrials.gov/study/NCT06995898) | Not Applicable | Recruiting | National Cancer Inst... | The Vanguard Study: Testing a New W... |
| [NCT06533644](https://clinicaltrials.gov/study/NCT06533644) | Phase 2 | Recruiting | Syncromune, Inc. | A Phase 2a Multicenter, Dose-Escala... |
| [NCT06972628](https://clinicaltrials.gov/study/NCT06972628) | Phase 2 | Recruiting | Ebrahim S Delpassand | 177Lu-PSMA-617 (Pluvicto) for the T... |
| [NCT06402357](https://clinicaltrials.gov/study/NCT06402357) | Phase 2 | Recruiting | University of Florid... | Salvage Focal Therapy Via High Inte... |
| [NCT06801236](https://clinicaltrials.gov/study/NCT06801236) | Phase 1 | Recruiting | Acerand Therapeutics... | A Phase 1 Study to Assess the Safet... |
| [NCT06764485](https://clinicaltrials.gov/study/NCT06764485) | Phase 3 | Recruiting | Celgene | A Phase 3, Two-part, Randomized, Op... |
| [NCT06780670](https://clinicaltrials.gov/study/NCT06780670) | Phase 2/Phase 3 | Recruiting | Novartis Pharmaceuti... | PSMAcTION: A Phase II/III, Open-lab... |
| [NCT06785636](https://clinicaltrials.gov/study/NCT06785636) | Phase 1/Phase 2 | Recruiting | Pathos AI, Inc. | A Phase 1b/2a, MultiCenter, Open- L... |
| [NCT06609005](https://clinicaltrials.gov/study/NCT06609005) | Phase 1/Phase 2 | Recruiting | Shenzhen Ionova Life... | A Phase 1 and Phase 2, Multi-Center... |
| [NCT06710379](https://clinicaltrials.gov/study/NCT06710379) | Phase 1 | Recruiting | Adcentrx Therapeutic... | A Phase 1a/b Study of ADRX-0405 in ... |
| [NCT06305598](https://clinicaltrials.gov/study/NCT06305598) | Phase 1 | Recruiting | Roswell Park Cancer ... | Bipolar Androgen Therapy in Metasta... |
| [NCT06568562](https://clinicaltrials.gov/study/NCT06568562) | Phase 2 | Recruiting | University of Utah | PRO-XL: A Phase II Study of XL092 i... |
| [NCT06691984](https://clinicaltrials.gov/study/NCT06691984) | Phase 3 | Recruiting | Amgen | A Phase 3, Open-label, Multicenter,... |
| [NCT06470243](https://clinicaltrials.gov/study/NCT06470243) | Phase 3 | Recruiting | SWOG Cancer Research... | A Phase III Study of Cabazitaxel Wi... |
| [NCT06228053](https://clinicaltrials.gov/study/NCT06228053) | Phase 2 | Recruiting | Syntrix Biosystems, ... | A Phase 2, Single-Arm Study of the ... |
| [NCT06629779](https://clinicaltrials.gov/study/NCT06629779) | Phase 3 | Recruiting | Pfizer | A PHASE 3, RANDOMIZED, DOUBLE BLIND... |
| [NCT06631521](https://clinicaltrials.gov/study/NCT06631521) | Phase 1 | Recruiting | AdventHealth | Neoadjuvant Darolutamide and Relugo... |
| [NCT06551324](https://clinicaltrials.gov/study/NCT06551324) | Phase 3 | Recruiting | Pfizer | A PHASE 3, RANDOMIZED, OPEN-LABEL S... |
| [NCT06145633](https://clinicaltrials.gov/study/NCT06145633) | Phase 2 | Recruiting | Fred Hutchinson Canc... | Vorinostat to Augment Response to 1... |
| [NCT06216249](https://clinicaltrials.gov/study/NCT06216249) | Phase 2 | Recruiting | Jonsson Comprehensiv... | A Phase 2 Randomized Trial in Patie... |
| [NCT06288113](https://clinicaltrials.gov/study/NCT06288113) | Phase 2 | Recruiting | Jonsson Comprehensiv... | Re-Treatment With 177Lu-PSMA-617 Mo... |
| [NCT06520345](https://clinicaltrials.gov/study/NCT06520345) | Phase 3 | Recruiting | Telix Pharmaceutical... | A Multinational, Multicenter, Prosp... |
| [NCT06457919](https://clinicaltrials.gov/study/NCT06457919) | Phase 1/Phase 2 | Recruiting | Memorial Sloan Kette... | A Phase 1b/2 Study Evaluating the A... |
| [NCT06353386](https://clinicaltrials.gov/study/NCT06353386) | Phase 1/Phase 2 | Recruiting | Merck Sharp & Dohme ... | MK-5684-01A Substudy: A Phase 1/2 U... |
| [NCT06395519](https://clinicaltrials.gov/study/NCT06395519) | Phase 1/Phase 2 | Recruiting | 858 Therapeutics, In... | A Study of PARG Inhibitor ETX-19477... |
| [NCT06369610](https://clinicaltrials.gov/study/NCT06369610) | Phase 2 | Recruiting | Mayo Clinic | Risk Stratified De-Escalated De-Int... |
| [NCT06049355](https://clinicaltrials.gov/study/NCT06049355) | Phase 2 | Recruiting | OHSU Knight Cancer I... | EMBark on RAdiation Therapy With a ... |
| [NCT06004661](https://clinicaltrials.gov/study/NCT06004661) | Phase 2 | Recruiting | Novartis Pharmaceuti... | An Open-label Dosimetry, Biodistrib... |
| [NCT06355336](https://clinicaltrials.gov/study/NCT06355336) | N/A | Recruiting | Cincinnati Cancer Ad... | Patient Reported Data on Prostate C... |
| [NCT06029998](https://clinicaltrials.gov/study/NCT06029998) | Phase 2 | Recruiting | University of Utah | A Phase II Study of Bortezomib in P... |
| [NCT06242470](https://clinicaltrials.gov/study/NCT06242470) | Phase 1 | Recruiting | MacroGenics | A Phase 1/1b First-in-Human, Open L... |
| [NCT05689021](https://clinicaltrials.gov/study/NCT05689021) | Phase 2 | Recruiting | Mayo Clinic | Phase 2 Study of CJNJ-67652000 (Nir... |
| [NCT06402331](https://clinicaltrials.gov/study/NCT06402331) | Phase 2 | Recruiting | Fusion Pharmaceutica... | A Phase 2, Randomized, Open-Label, ... |
| [NCT05806515](https://clinicaltrials.gov/study/NCT05806515) | Phase 2 | Recruiting | SWOG Cancer Research... | S2210 A Phase II Study of Neoadjuva... |
| [NCT06161506](https://clinicaltrials.gov/study/NCT06161506) | Phase 2 | Recruiting | National Cancer Inst... | A Phase II Trial of Surface Electri... |
| [NCT05765500](https://clinicaltrials.gov/study/NCT05765500) | Phase 2 | Recruiting | Dana-Farber Cancer I... | RecoverPC: A Phase 2 Study of RElug... |
| [NCT06177171](https://clinicaltrials.gov/study/NCT06177171) | Phase 1 | Recruiting | Pamela Munster | A Phase I/Ib Study of Olaparib and ... |
| [NCT06046040](https://clinicaltrials.gov/study/NCT06046040) | Phase 1 | Recruiting | University of Pennsy... | Phase I, Open-Label Study of Dually... |
| [NCT06205316](https://clinicaltrials.gov/study/NCT06205316) | Phase 3 | Recruiting | Mayo Clinic | Randomized Phase III Trial of SBRT ... |
| [NCT06190899](https://clinicaltrials.gov/study/NCT06190899) | Phase 1/Phase 2 | Recruiting | Celcuity Inc | A Phase 1/2, Open-Label, Randomized... |
| [NCT06659614](https://clinicaltrials.gov/study/NCT06659614) | N/A | Recruiting | Abramson Cancer Cent... | Prostate Tissue Biobank for People ... |
| [NCT05534646](https://clinicaltrials.gov/study/NCT05534646) | Phase 2 | Recruiting | Edwin Posadas, MD | Phase II Study of Apalutamide With ... |
| [NCT06100705](https://clinicaltrials.gov/study/NCT06100705) | Phase 2 | Recruiting | Yale University | A Single Arm Open-label, Phase II S... |

*... and 50 more trials (see trials.csv for full list)*
